Cholesstrinol Lowers C-Reactive Protein
SourceOne Global Partners (Chicago) organized an open-label trial on 84 hypercholestermic men and women to see if a combination of polymethoxylated flavones and tocotrienols (Chollestrinol HP) could reduce CRP levels.
Clinical science suggests that C-reactive protein (CRP) is a suitable biomarker for assessing risk of cardiovascular disease and inflammation. With this in mind, SourceOne Global Partners (Chicago) organized an open-label trial on 84 hypercholestermic men and women to see if a combination of polymethoxylated flavones and tocotrienols (Chollestrinol HP) could reduce CRP levels.
After 12 weeks, all patients reportedly saw decreases in high-sensitivity CRP by an average of 2.4 mg/l to 1.4 mg/l. Twenty-one patients reportedly responded even better, averaging a drop from 3.6 mg/l to 1.7 mg/l.
Andreas Supersaxo, R&D director for Vesifact (Baar, Switzerland) and a member of SourceOne’s scientific board, notes the significance: “The American Heart Association has designated a CRP concentration of less than 1 mg/l as representing low risk for cardiovascular disease, whereas concentrations of 1.0 to 3.0 mg/l and greater than 3.0 mg/l have been designated as representing average risk and high risk, respectively.”
